Livimplant GmbH

What Livimplant GmbH does

Livimplant GmbH is a privately held German company (GmbH structure) headquartered in Starnberg, Germany, that develops and sells innovative cell-based therapies targeting lesions and diseases of tendons, joints, cartilage, and bones. The company's functional focus is regenerative medicine within the musculoskeletal field, where it positions itself around biological, cell-based treatment modalities rather than device- or small-molecule-based approaches. Its website (livimplant.de) is the stated public-facing channel, and the firm operates with a micro headcount of 1-10 employees, consistent with an early-stage or specialist clinical/research-stage biotech.

The underlying business is built on proprietary cell-based therapy know-how applied to orthopedic and sports-medicine indications; however, the source data does not disclose specific products, manufacturing processes, clinical-stage assets, or platform architecture details. There are no disclosed patents, trademarks, regulatory approvals (e.g., EMA ATMP classification, CE marks, or FDA pathways), clinical trial registrations, or named partners in the input. No management team, board, or scientific advisory information is provided.

The revenue model is not characterized in the available data: no pricing, distribution channels, customer segments, or sales metrics are disclosed. Given the headcount (1-10), absence of funding history, and absence of product-level disclosures, the company appears to be operating at a pre-commercial or very early commercial scale, with go-to-market mechanics — direct-to-clinic sales, licensing, hospital partnerships, or distribution — unverified. The limited source material constrains any deeper inference on unit economics, customer profile, or commercial traction.

Name

Livimplant GmbH

Legal name

Livimplant GmbH

Website

https://livimplant.de

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Livimplant GmbH is a privately held German biotech in Starnberg that develops and sells cell-based therapies for musculoskeletal conditions affecting tendons, joints, cartilage, and bones, operating with a 1-10 person team.

Ownership category

akta.pro rank

Headquarters

HQ city

Starnberg

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Core offering

Livimplant GmbH develops and sells innovative cell-based therapies for lesions and diseases of tendons, joints, cartilage, and bones. The company focuses on regenerative, biologic treatment approaches within the orthopedic and musculoskeletal field.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell-based tendon therapies
• Cell-based joint therapies
• Cell-based cartilage therapies Cell-based biologic therapies for cartilage lesions and cartilage diseases, developed for use in cartilage repair and regenerative orthopedic applications.
• Cell-based bone therapies Cell-based biologic therapies addressing bone lesions and bone diseases, designed for bone regeneration and repair in orthopedic settings.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Emerging players

• Orthocell Ltd: Australia-listed regenerative medicine company developing autologous cell therapies for tendon, cartilage, and bone indications. Closely mirrors Livimplant's multi-tissue musculoskeletal focus and small-cap, single-platform profile.
• Geistlich Pharma: Swiss specialist in regenerative dental and orthopedic matrices (e.g., Chondro-Gide for cartilage regeneration). Overlaps in musculoskeletal regeneration using biologic/matrix-based approaches — complementary to Livimplant's cell-based approach.
• Mesoblast Limited: Australia-listed cell therapy developer with mesenchymal stem cell–based products targeting inflammatory and orthopedic conditions (e.g., cartilage/bone indications). Comparable as an early-to-mid-stage cell-therapy developer working in musculoskeletal disease.

Broad incumbents

• Smith & Nephew: Global orthopedic and sports medicine major with a biologics/regenerative portfolio including cartilage repair products (e.g., BioCartilage, Regeneten for tendon repair). Comparable target indications (tendon, cartilage, joint) and serves as both competitor and potential acquirer of Livimplant-type assets.
• Bioventus: U.S. orthobiologics company focused on bone, joint, and soft-tissue healing (e.g., platelet-rich plasma, allograft solutions). Comparable therapeutic areas (tendon, joint, bone) and the same sports medicine/orthopedic buyer base.
• Arthrex: Privately held global orthopedic device leader with a wide biologics/regenerative portfolio addressing cartilage, tendon, and bone repair. Comparable clinical indications and customer base (orthopedic surgeons, sports medicine specialists).
• Anika Therapeutics: U.S. orthobiologics company with hyaluronic-acid joint preservation therapies and regenerative product lines (e.g., cartilage repair / tendon applications). Overlaps with Livimplant's joint and soft-tissue targets from a different but related modality.
• Stryker Corporation: Global orthopedic major with biologics and sports medicine franchises (e.g., Mako robotic surgery, cartilage restoration partnerships). Competes for the same surgeon customers and tendons/joints/cartilage clinical indications.

Direct peers

• Vericel Corporation: U.S. company commercializing MACI, an autologous cultured chondrocyte implant for cartilage repair. Directly comparable in product type (autologous cell-based cartilage implant), regulatory pathway, and target patient population.
• CO.DON AG / TETEC: Berlin-based developer of autologous chondrocyte-based cell therapy for articular cartilage defects (e.g., co.don chondrosphere/spherox). Closest direct peer to Livimplant: same German origin, same autologous cell-therapy approach, same musculoskeletal regeneration focus.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat1 record

Key risks6 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/livimplant-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Livimplant GmbH